A Form 4 filed with the SEC on September 9, 2026, discloses that John W. Smither, a director of NewAmsterdam Pharma Co N.V. (NASDAQ:NAMS), sold 1,600 ordinary shares on September 4, 2026, at a weighted average price of $25.32 per share to cover tax obligations tied to a prior restricted stock unit vesting.
Key Highlights
- Reporting person: John W. Smither, identified as a director of NewAmsterdam Pharma Co N.V.
- Transaction date: September 4, 2026, with 1,600 ordinary shares disposed of under transaction code S.
- Sale price range: Shares were sold in multiple transactions at prices ranging from $25.24 to $25.37 per share, with a weighted average of $25.32.
- Stated purpose: According to the filing, the sale was made "to generate proceeds to satisfy the Reporting Person's tax obligations in connection with the prior vesting of restricted stock units."
- Post-transaction ownership: Smither beneficially owned 8,760 ordinary shares following the transaction, held directly.
- Unvested RSUs included: Of the 8,760 shares reported, 8,040 are ordinary shares subject to restricted stock unit awards that remain subject to vesting, according to the filing.
Director Share Sale Details at NewAmsterdam Pharma
NewAmsterdam Pharma Co N.V., a pharmaceutical company listed on NASDAQ under the symbol NAMS and headquartered in Naarden, Netherlands, was the issuer named in this Form 4 filing. The filing covers a single non-derivative securities transaction in which director John W. Smither disposed of 1,600 ordinary shares on September 4, 2026.
The filing states that the reported transaction reflects a sale executed to generate proceeds to satisfy tax obligations arising from the prior vesting of restricted stock units. The shares were sold across multiple transactions at prices ranging from $25.24 to $25.37 per share, producing a weighted average sale price of $25.32. The filing further notes that Smither undertakes to provide full information regarding the number of shares sold in each individual transaction upon request by the issuer, any security holder, or SEC staff.
Following the reported sale, Smither's total direct beneficial ownership stood at 8,760 ordinary shares. The filing discloses that 8,040 of those shares are subject to restricted stock unit awards that have not yet vested, meaning the balance of fully vested, unrestricted shares directly held was 720 after the transaction. No derivative securities transactions were reported in Table II of the filing.
What Was Disclosed
The Form 4 filed September 9, 2026, reports that NewAmsterdam Pharma Co N.V. director John W. Smither sold 1,600 ordinary shares on September 4, 2026, at a weighted average price of $25.32, retaining direct beneficial ownership of 8,760 shares, of which 8,040 remain subject to vesting.



Please wait processing your request...